Fig. 36From: Molecular docking studies of coumarin hybrids as potential acetylcholinesterase, butyrylcholinesterase, monoamine oxidase A/B and β-amyloid inhibitors for Alzheimer’s diseaseMarketed anti-AD drugs. For cholinergic drugs, inhibitory activity ranges on AChE and BuChE are reportedBack to article page